United States POSIMIR Drug Insight and Market Forecast - 2032

This “POSIMIR Drug Insight and Market Forecast – 2032” report provides comprehensive insights about POSIMIR for acute pain in the United States. A detailed picture of the POSIMIR for acute pain in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the POSIMIR for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POSIMIR market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary

POSIMIR (bupivacaine solution) for infiltration use is a novel and proprietary product that combines the strength of 660 mg of bupivacaine base with the innovative SABER platform technology, enabling continuous sustained delivery of a non-opioid local analgesic over 3 days in adults. POSIMIR contains more bupivacaine than any other approved single-dose sustained-release bupivacaine product. POSIMIR is administered into the subacromial space under direct arthroscopic visualization at the end of the surgery, where it continuously releases bupivacaine for 72 hours or more. Durect is discussing with potential partners licensing commercialization rights to POSIMIR, for which Durect holds worldwide rights.

Dosage and Administration

The recommended dose is a 5 mL single-dose vial, 660 mg/5 mL (132 mg/mL).

Mechanism of Action

Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve by slowing the propagation of the nerve impulse and reducing the rate of the rising action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the POSIMIR description, mechanism of action, dosage and administration, research and development activities in acute pain.
• Elaborated details on POSIMIR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the POSIMIR research and development activities in acute pain across the United States.
• The report also covers the patents information with expiry timeline around POSIMIR.
• The report contains forecasted sales of POSIMIR for acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute pain.
• The report also features the SWOT analysis with analyst views for POSIMIR in acute pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publishing team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

POSIMIR Analytical Perspective

In-depth POSIMIR Market Assessment

This report provides a detailed market assessment of POSIMIR for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

POSIMIR Clinical Assessment

The report provides the clinical trials information of POSIMIR for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence POSIMIR dominance.
• Other emerging products for acute pain are expected to give tough market competition to POSIMIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of POSIMIR in acute pain.
• Our in-depth analysis of the forecasted sales data of POSIMIR from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the POSIMIR in acute pain.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of POSIMIR?
• What is the clinical trial status of the study related to POSIMIR in acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the POSIMIR development?
• What are the key designations that have been granted to POSIMIR for acute pain?
• What is the forecasted market scenario of POSIMIR for acute pain?
• What are the forecasted sales of POSIMIR in the United States?
• What are the other emerging products available and how are these giving competition to POSIMIR for acute pain?
• Which are the late-stage emerging therapies under development for the treatment of acute pain?

This product will be delivered within 2 business days.